These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 31322247

  • 1. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Ishikura N, Yorozu K, Kurasawa M, Yanagisawa M, Sugimoto M, Yamamoto K.
    Oncol Rep; 2019 Sep; 42(3):1057-1065. PubMed ID: 31322247
    [Abstract] [Full Text] [Related]

  • 2. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Ishikura N, Yanagisawa M, Noguchi-Sasaki M, Iwai T, Yorozu K, Kurasawa M, Sugimoto M, Yamamoto K.
    Anticancer Res; 2017 Feb; 37(2):623-629. PubMed ID: 28179309
    [Abstract] [Full Text] [Related]

  • 3. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H, Fukami T, Yotsumoto F, Ueda T, Hikita S, Takahashi Y, Kondo H, Kuroki M, Miyamoto S.
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [Abstract] [Full Text] [Related]

  • 4. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.
    Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
    [Abstract] [Full Text] [Related]

  • 5. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Bizzaro F, Falcetta F, D'Agostini E, Decio A, Minoli L, Erba E, Alessandro Peccatori F, Scanziani E, Colombo N, Zucchetti M, Bani MR, Ubezio P, Giavazzi R.
    Int J Cancer; 2018 Nov 01; 143(9):2187-2199. PubMed ID: 29752717
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.
    Liu Y, Chen L, He X, Fan L, Yang G, Chen X, Lin X, DU L, Li Z, Ye H, Mao Y, Zhao X, Wei Y.
    Int J Gynecol Cancer; 2008 Nov 01; 18(4):652-9. PubMed ID: 17892458
    [Abstract] [Full Text] [Related]

  • 7. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
    Suzuki N, Aoki D, Oie S, Horiuchi M, Hasegawa Y, Ezawa S, Suzuki A, Susumu N, Hosoi F, Kitazato K, Nozawa S.
    Gynecol Oncol; 2004 Sep 01; 94(3):643-9. PubMed ID: 15350353
    [Abstract] [Full Text] [Related]

  • 8. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T, Sugimoto M, Harada S, Yorozu K, Kurasawa M, Yamamoto K.
    Oncol Rep; 2016 Aug 01; 36(2):626-32. PubMed ID: 27350037
    [Abstract] [Full Text] [Related]

  • 9. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK.
    Mol Cancer Ther; 2015 Dec 01; 14(12):2677-86. PubMed ID: 26516159
    [Abstract] [Full Text] [Related]

  • 10. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
    Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, Scanziani E, Belotti D, Giavazzi R.
    Br J Cancer; 2012 Jul 10; 107(2):360-9. PubMed ID: 22713663
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T, Takeshima N, Sugiyama T.
    Int J Clin Oncol; 2019 Jan 10; 24(1):103-114. PubMed ID: 30030657
    [Abstract] [Full Text] [Related]

  • 12. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M, Mabuchi S, Kishimoto T, Hisamatsu T, Matsumoto Y, Sasano T, Takahashi R, Sawada K, Takahashi K, Takahashi T, Hamasaki T, Kimura T.
    Int J Gynecol Cancer; 2014 Jun 10; 24(5):829-37. PubMed ID: 24844217
    [Abstract] [Full Text] [Related]

  • 13. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M.
    Clin Cancer Res; 2008 Dec 01; 14(23):7781-9. PubMed ID: 19047105
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A.
    Cancer Res; 2003 May 15; 63(10):2447-53. PubMed ID: 12750265
    [Abstract] [Full Text] [Related]

  • 15. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
    Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M.
    Oncol Rep; 2007 Jul 15; 18(1):47-51. PubMed ID: 17549344
    [Abstract] [Full Text] [Related]

  • 16. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O.
    Mol Oncol; 2012 Aug 15; 6(4):418-27. PubMed ID: 22521242
    [Abstract] [Full Text] [Related]

  • 17. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A.
    Mol Cancer Ther; 2007 Jul 15; 6(7):2003-11. PubMed ID: 17620430
    [Abstract] [Full Text] [Related]

  • 18. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N, Oranratanaphan S, Termrungruanglert W, Lertkhachonsuk R, Vasurattana A.
    Asian Pac J Cancer Prev; 2013 Jul 15; 14(3):2131-5. PubMed ID: 23679331
    [Abstract] [Full Text] [Related]

  • 19. Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice.
    Yahuafai J, Asai T, Oku N, Siripong P.
    Biol Pharm Bull; 2018 Jul 15; 41(7):1103-1106. PubMed ID: 29962406
    [Abstract] [Full Text] [Related]

  • 20. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
    Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E.
    Gynecol Oncol; 2016 Sep 15; 142(3):465-70. PubMed ID: 27184721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.